09/778,926.

```
FILE 'HOME' ENTERED AT 15:49:47 ON 19 MAY 2005

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.63       0.63

FILE 'BIOSIS' ENTERED AT 15:51:13 ON 19 MAY 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:51:13 ON 19 MAY 2005

FILE 'CAPLUS' ENTERED AT 15:51:13 ON 19 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:51:13 ON 19 MAY 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 15:51:13 ON 19 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s bovine spongiform encephalopathy and electrophoresis
L1          554 BOVINE SPONGIFORM ENCEPHALOPATHY AND ELECTROPHORESIS

=> s l1 and glycoform
L2            9 L1 AND GLYCOFORM

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3            9 DUP REM L2 (0 DUPLICATES REMOVED)

=> d l3 bib abs 1-9

L3   ANSWER 1 OF 9  USPATFULL on STN
AN     2004:334822  USPATFULL
TI     Diagnostic method
IN     Stack, Michael James, Surrey, UNITED KINGDOM
       Chaplin, Melanie Jane, Surrey, UNITED KINGDOM
       Clark, Jemma, Surrey, UNITED KINGDOM
PI     US 2004265904      A1   20041230
AI     US 2004-493572     A1   20040513 (10)
       WO 2002-GB4789          20021023
PRAI   GB 2001-25606       20011025
DT     Utility
FS     APPLICATION
LREP   NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA,
       22201-4714
CLMN   Number of Claims: 16
ECL    Exemplary Claim: 1
DRWN   4 Drawing Page(s)
LN.CNT 692
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     A method for typing a strain of a transmissible spongiform
       encephalophathy (TSE) in an infected animal, said method comprising: a)
       separating a sample of abnormal prion protein on the basis of molecular
       weight and/or glycoform ratios, and detecting the separated
       forms; b) detecting in the sample the presence of a peptide sequence,
       wherein the presence of said peptide sequence within abnormal prion
       protein is capable of distinguishing a particular strain of TSE from
       others, and c) using the results of (a) and (b) to determine the type of
       TSE strain present in the sample. The method may be used in particular
       to distinguish BSE from scrapie in sheep.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 9 USPATFULL on STN
AN 2004:307835 USPATFULL
TI Method
IN Fisher, Elizabeth Mary Claire, London, UNITED KINGDOM
Lloyd, Sarah Elizabeth, London, UNITED KINGDOM
Collinge, John, Queen Square, UNITED KINGDOM
PI US 2004242511 A1 20041202
AI US 2004-470014 A1 20040122 (10)
WO 2002-GB256 20020122
PRAI GB 2001-1763 20010123
DT Utility
FS APPLICATION
LREP MARSHALL, GERSTEIN & BORUN LLP, 6300 SEARS TOWER, 233 S. WACKER DRIVE, CHICAGO, IL, 60606
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3578
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method for the detection of prions in a sample comprising the steps of contacting one or more test animals with the sample; incubating the test animals; monitoring the test animals for adverse effects or death; and optionally performing a biopsy on the test animals that display adverse effects or death for evidence of prions; wherein the test animals have prion incubation times of 196 days or less.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 9 USPATFULL on STN
AN 2004:222053 USPATFULL
TI Endomannosidases in the modification of glycoproteins in eukaryotes
IN Hamilton, Stephen, Enfield, NH, UNITED STATES
PI US 2004171826 A1 20040902
AI US 2003-695243 A1 20031027 (10)
RLI Continuation-in-part of Ser. No. US 2003-371877, filed on 20 Feb 2003, PENDING
DT Utility
FS APPLICATION
LREP James F. Haley, Jr., Esq., c/o FISH & NEAVE, 1251 Avenue of the Americas, New York, NY, 10020-1104
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2983
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally relates to methods of modifying the glycosylation structures of recombinant proteins expressed in fungi or other lower eukaryotes, to more closely resemble the glycosylation of proteins from higher mammals, in particular humans. The present invention also relates to novel enzymes and, nucleic acids encoding them and, hosts engineered to express the enzymes, methods for producing modified glycoproteins in hosts and modified glycoproteins so produced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 9 USPATFULL on STN
AN 2004:171948 USPATFULL
TI Method
IN Enari, Masato, Chuo-ku, JAPAN
Flechsig, Eckhard, Versbacher, GERMANY, FEDERAL REPUBLIC OF
Collinge, John, Queen, UNITED KINGDOM
Weismann, Charles, London, UNITED KINGDOM
PI US 2004132109 A1 20040708
AI US 2004-470022 A1 20040109 (10)
WO 2002-GB257 20020122

PRAI GB 2001-1762 20010123
DT Utility
FS APPLICATION
LREP MARSHALL, GERSTEIN & BORUN LLP, 6300 SEARS TOWER, 233 S. WACKER DRIVE, CHICAGO, IL, 60606
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3141
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods for determining the presence of prions in a tissue/organ or fluid therefrom; said method comprising the steps of: contacting the tissue/organ with one or more devices, wherein said devices are capable of binding prions; removing said devices from contact with said tissue/organ; determining if said devices are binding prions wherein the device is contacted with the tissue/organ for 120 minutes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 9 USPATFULL on STN
AN 2003:60077 USPATFULL
TI Immunological agents specific for prion protein (PRP)
IN Sy, Man-Sun, Shaker Heights, OH, United States
Gambetti, Pierluigi, Shaker Heights, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
PI US 6528269 B1 20030304
AI US 1998-204816 19981203 (9)
PRAI US 1998-90165P 19980622 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P
LREP Fay, Sharpe, Fagan, Minnich & McKee, LLP
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 1433
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a panel of monoclonal antibodies (Mabs) specific for murine prion protein PrP.sup.c. These Mabs can be applied to immunoblotting, cell surface immunofluorescent staining and immunohistochemistry at light and electron microscopy. Additionally, these Mabs recognize both the normal (PrP.sup.c) and protease-resistant (PrP.sup.res) isoforms of PrP. Some Mabs are species restricted, while others react with PrP from a broad range of mammals including mice, humans, monkeys, cows, sheep, squirrels and hamsters. Moreover, several of the Mabs selectively recognize different PrP glycoforms as well as the metabolic fragments of PrP.sup.c. These newly generated PrP.sup.c antibodies are useful for exploring the biology of PrP.sup.c and to establish the diagnosis of prion diseases in both humans and animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 9 USPATFULL on STN
AN 2002:251169 USPATFULL
TI Method of detecting PrP protein and kits therefor
IN Voelkel, Dirk, Vienna, AUSTRIA
Zimmermann, Klaus, Vienna, AUSTRIA
Turecek, Peter, Klosterneuburg, AUSTRIA
Schwarz, Hans-Peter, Vienna, AUSTRIA
PI US 2002137114 A1 20020926
AI US 2002-51413 A1 20020118 (10)
PRAI US 2001-263022P 20010119 (60)
DT Utility
FS APPLICATION
LREP Baxter Healthcare Corporation, P.O. Box 15210, Irvine, CA, 92614
CLMN Number of Claims: 49

ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 997
CAS İNDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method for the detection of neurological disorders in a patient comprising (a) measuring the concentration of PrP protein in a biological fluid sample of said patient; and (b) determining whether said concentration of said PrP protein is above or below a predetermined threshold value, whereby the concentration above said predetermined threshold value identifies a patient with a neurological disorder, a method for the detection and quantification of PrP protein and pathogenic PrP.sup.res protein in a sample, and a kit comprising a set of reagents to determine the concentration of PrP protein and pathogenic PrP.sup.res protein in a sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 9 USPATFULL on STN
AN 2002:157046 USPATFULL
TI Diagnosis of spongiform encephalopathy
IN Collinge, John, London, UNITED KINGDOM
PI US 2002081645 A1 20020627
AI US 2001-778926 A1 20010206 (9)
RLI Continuation of Ser. No. US 1999-291215, filed on 14 Apr 1999, ABANDONED
PRAI GB 1996-21469 19961015
GB 1996-21885 19961021
DT Utility
FS APPLICATION
LREP HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for typing a sample of a prion or spongiform encephalopathy disease, a kit suitable for use in such a typing method, a method for identifying infection in an animal and/or tissue of **bovine spongiform encephalopathy** (BSE), a method for assessing and/or predicting the susceptibility of an animal to BSE, a kit for use in such an assessment and/or prediction method, a method for the treatment of a prion disease, and compounds suitable for such a method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 9 USPATFULL on STN
AN 2002:78467 USPATFULL
TI Mammalian proteins; related reagents and methods
IN Bazan, J. Fernando, Palo Alto, CA, UNITED STATES
PI US 2002042122 A1 20020411
AI US 2000-745003 A1 20001220 (9)
PRAI US 1999-172090P 19991223 (60)
DT Utility
FS APPLICATION
LREP DNAX RESEARCH INSTITUTE, LEGAL DEPARTMENT, 901 CALIFORNIA AVENUE, PALO ALTO, CA, 94304
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian polypeptides, isolated proteins, and fragments thereof including the polynucleotides encoding them. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 9 MEDLINE on STN
AN 2000237810 MEDLINE
DN PubMed ID: 10773427.
TI Comparison of French natural scrapie isolates with **bovine spongiform encephalopathy** and experimental scrapie infected sheep.
AU Baron T G; Madec J Y; Calavas D; Richard Y; Barillet F
CS Agence Francaise de Securite Sanitaire des Aliments, 69364, Lyon, France.. t.baron@lyon.afssa.fr
SO Neuroscience letters, (2000 Apr 28) 284 (3) 175-8.
Journal code: 7600130. ISSN: 0304-3940.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200006
ED Entered STN: 20000622
Last Updated on STN: 20000622
Entered Medline: 20000613
AB We compared the **glycoform** pattern of the abnormal prion protein (PrP(Sc)) detected by immunoblotting in 21 sheep with natural scrapie, from 21 different outbreaks identified in France since 1996, with a **bovine spongiform encephalopathy** (BSE)-infected sheep. All the natural scrapie isolates had a higher molecular mass of the unglycosylated PrP(Sc) than in BSE-infected sheep. In the latter case, this molecular mass appeared identical to that found in the CH 1641 experimental scrapie strain (type C pattern), whereas in natural scrapie cases it was similar to that found in the SSBP/1 experimental scrapie strains. These results suggest that all French natural scrapie isolates studied so far would belong, as SSBP/1, to the group of scrapie cases with type A electrophoretic pattern.

=> d his

(FILE 'HOME' ENTERED AT 15:49:47 ON 19 MAY 2005)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:51:13 ON 19 MAY 2005
L1 554 S BOVINE SPONGIFORM ENCEPHALOPATHY AND ELECTROPHORESIS
L2 9 S L1 AND GLYCOFORM
L3 9 DUP REM L2 (0 DUPLICATES REMOVED)

=> s prion and typing'
MISMATCHED QUOTE 'TYPING''
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s prion and typing
L4 479 PRION AND TYPING

=> s l4 and glycoform?
L5 21 L4 AND GLYCOFORM?

=> s l5 and electrophoresis
L6 15 L5 AND ELECTROPHORESIS

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7 15 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l7 and ratio?
L8 13 L7 AND RATIO?

=> d l8 bib abs 1-13

L8 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:335409 CAPLUS
DN 138:317152
TI Diagnostic method
IN Stack, Michael James; Chaplin, Melanie Jane; Clark, Jemma
PA The Secretary of State for Environment, Food and Rural Affairs, UK
SO PCT Int. Appl., 30 pp.
    CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003036303	A1	20030501	WO 2002-GB4789	20021023
	WO 2003036303	C1	20030918		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2462581	AA	20030501	CA 2002-2462581	20021023
	GB 2396009	A1	20040609	GB 2004-6547	20021023
	GB 2396009	B2	20050316		
	EP 1442303	A1	20040804	EP 2002-770097	20021023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005506551	T2	20050303	JP 2003-538748	20021023
	US 2004265904	A1	20041230	US 2004-493572	20040513
PRAI	GB 2001-25606	A	20011025		
	WO 2002-GB4789	W	20021023		

AB A method for **typing** a strain of a transmissible spongiform encephalophathy (TSE) in an infected animal, said method comprising: (a) separating a sample of abnormal **prion** protein on the basis of mol. weight and/or **glycoform ratios**, and detecting the separated forms; (b) detecting in the sample the presence of a peptide sequence, wherein the presence of said peptide sequence within abnormal **prion** protein is capable of distinguishing a particular strain of TSE from others, and (c) using the results of (a) and (b) to determine the type of TSE strain present in the sample. The method may be used in particular to distinguish BSE from scrapie in sheep.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
           ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 13 USPATFULL on STN
AN 2005:107273 USPATFULL
TI Method to type **prion** proteins
IN Collinge, John, London, UNITED KINGDOM
    Wadsworth, Jonathan David Frank, London, UNITED KINGDOM
PA D-Gen Limited, London, UNITED KINGDOM (non-U.S. corporation)
PI US 6887676 B1 20050503
    WO 2000062068 20001019
AI US 2001-958517 20000407 (9)
    WO 2000-GB1327 20000407
                    20020212 PCT 371 date
PRAI GB 2001-9908059 19990409
DT Utility
FS GRANTED
EXNAM Primary Examiner: Housel, James; Assistant Examiner: Lucas, Zachariah
LREP Nikolai & Mersereau PA, Mersereau, C. G.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 983
AB The invention relates to methods and materials for use in the

typing, diagnosis, prevention and/or treatment of **prion** disease.

L8 ANSWER 3 OF 13 USPATFULL on STN
AN 2005:63014 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2005054051 A1 20050310
AI US 2004-922142 A1 20040820 (10)
RLI Division of Ser. No. US 2001-832929, filed on 12 Apr 2001, PENDING
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 17526
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 13 USPATFULL on STN
AN 2004:334822 USPATFULL
TI Diagnostic method
IN Stack, Michael James, Surrey, UNITED KINGDOM
Chaplin, Melanie Jane, Surrey, UNITED KINGDOM
Clark, Jemma, Surrey, UNITED KINGDOM
PI US 2004265904 A1 20041230
AI US 2004-493572 A1 20040513 (10)
WO 2002-GB4789 20021023
PRAI GB 2001-25606 20011025
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201-4714
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 692
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for **typing** a strain of a transmissible spongiform encephalophathy (TSE) in an infected animal, said method comprising: a) separating a sample of abnormal **prion** protein on the basis of molecular weight and/or **glycoform ratios**, and detecting the separated forms; b) detecting in the sample the presence of a peptide sequence, wherein the presence of said peptide sequence within abnormal **prion** protein is capable of distinguishing a particular strain of TSE from others, and c) using the results of (a) and (b) to determine the type of TSE strain present in the sample. The method may be used in particular to distinguish BSE from scrapie in sheep.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 13 USPATFULL on STN
AN 2004:314570 USPATFULL
TI 47153, A HUMAN GLYCOSYLTRANSFERASE FAMILY MEMBER AND USES THEREFOR
IN Meyers, Rachel, Newton, MA, UNITED STATES
Rosenfeld, Julie Beth, Sharon, MA, UNITED STATES
PI US 2004248242 A1 20041209
US 6849437 B2 20050201
AI US 2002-113709 A1 20020328 (10)
PRAI US 2001-279647P 20010328 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47153 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47153 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47153 gene has been introduced or disrupted. The invention still further provides isolated 47153 proteins, fusion proteins, antigenic peptides and anti-47153 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 13 USPATFULL on STN
AN 2004:221354 USPATFULL
TI ALBUMIN FUSION PROTEINS
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2004171123 A1 20040902
AI US 2001-832929 A1 20010412 (9)
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 17424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 13 USPATFULL on STN
AN 2004:107607 USPATFULL
TI 47174, a novel human glycosyltransferase and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004082007 A1 20040429
AI US 2003-713345 A1 20031114 (10)
RLI Division of Ser. No. US 2001-973457, filed on 9 Oct 2001, GRANTED, Pat.

No. US 6703230
PRAI US 2000-238849P 20001006 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47174 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47174 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47174 gene has been introduced or disrupted. The invention still further provides isolated 47174 proteins, fusion proteins, antigenic peptides and anti-47174 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing neurological disorders are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 13 USPATFULL on STN
AN 2003:318632 USPATFULL
TI Novel human transferase family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
Leiby, Kevin R., Natick, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Olandt, Peter J., Newton, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Hunter, John J., Somerville, MA, UNITED STATES
PI US 2003224376 A1 20031204
AI US 2002-184648 A1 20020627 (10)
RLI Continuation-in-part of Ser. No. US 2001-815028, filed on 22 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-801220, filed on 7 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-816714, filed on 23 Mar 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-844948, filed on 27 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-861164, filed on 18 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-883060, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-962678, filed on 25 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-973457, filed on 9 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2002-72285, filed on 8 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2001-817910, filed on 26 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-842528, filed on 25 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-882836, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-882872, filed on 15 Jun 2001, ABANDONED
PRAI WO 2001-US9358 20010322
WO 2001-US7269 20010307
WO 2001-US9468 20010323
WO 2001-US13805 20010427
WO 2001-US16292 20010518
WO 2001-US19138 20010615
WO 2001-US29963 20010925
WO 2002-US3736 20020208
WO 2001-US9633 20010326
WO 2001-US40607 20010425
WO 2001-US19543 20010615
WO 2001-US19153 20010615
US 2000-191964P 20000324 (60)

US 2000-187456P 20000307 (60)
US 2000-191865P 20000324 (60)
US 2000-200604P 20000428 (60)
US 2000-205408P 20000519 (60)
US 2000-212079P 20000615 (60)
US 2000-235044P 20000925 (60)
US 2000-238849P 20001006 (60)
US 2001-267494P 20010208 (60)
US 2000-192092P 20000324 (60)
US 2000-199500P 20000425 (60)
US 2000-211730P 20000615 (60)
US 2000-212077P 20000615 (60)
DT Utility
FS APPLICATION
LREP Theodore R. Allen, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 125 Drawing Page(s)
LN.CNT 66695
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 13 USPATFULL on STN
AN 2002:294703 USPATFULL
TI 47174, a novel human glycosyltransferase and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2002164746 A1 20021107
US 6703230 B2 20040309
AI US 2001-973457 A1 20011009 (9)
PRAI US 2000-238849P 20001006 (60)
DT Utility
FS APPLICATION
LREP LOUIS MEYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4577
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47174 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47174 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47174 gene has been introduced or disrupted. The invention still further provides isolated 47174 proteins, fusion proteins, antigenic peptides and anti-47174 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of

modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing neurological disorders are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 13 USPATFULL on STN
AN 2002:280065 USPATFULL
TI 32624, a novel human UDP-glucuronosyl and glycosyl transferase family member and uses thereof
IN Leiby, Kevin R., Natick, MA, UNITED STATES
PI US 2002155499 A1 20021024
AI US 2001-962678 A1 20010925 (9)
PRAI US 2000-235044P 20000925 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32624 nucleic acid molecules, which encode novel UDP-glucuronosyl and glycosyl transferase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32624 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32624 gene has been introduced or disrupted. The invention still further provides isolated 32624 proteins, fusion proteins, antigenic peptides and anti-32624 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 13 USPATFULL on STN
AN 2002:228315 USPATFULL
TI 32626, a novel human UDP-glycosyltransferase and uses thereof
IN Leiby, Kevin R., Natick, MA, UNITED STATES
Spaltmann, Frank, Cambridge, MA, UNITED STATES
Cook, William James, Natick, MA, UNITED STATES
PI US 2002123475 A1 20020905
AI US 2001-895728 A1 20010629 (9)
PRAI US 2000-215749P 20000630 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4203
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32626 nucleic acid molecules, which encode novel UDP-glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32626 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32626 gene has been introduced or disrupted. The invention still further provides isolated 32626 proteins, fusion proteins, antigenic peptides and anti-32626 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 13 USPATFULL on STN

AN 2002:199265 USPATFULL
TI 26199, 33530, 33949, 47148, 50226, and 58764, novel human transferase family members and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
MacBeth, Kyle, Boston, MA, UNITED STATES
PI US 2002107376 A1 20020808
AI US 2001-924358 A1 20010806 (9)
PRAI US 2000-229300P 20000901 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC, 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 6380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, or 58764 nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, or 58764 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, or 58764 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, or 58764 proteins, fusion proteins, antigenic peptides and anti-26199, -33530, -33949, -47148, -50226, or -58764 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 13 USPATFULL on STN
AN 2002:157046 USPATFULL
TI Diagnosis of spongiform encephalopathy
IN Collinge, John, London, UNITED KINGDOM
PI US 2002081645 A1 20020627
AI US 2001-778926 A1 20010206 (9)
RLI Continuation of Ser. No. US 1999-291215, filed on 14 Apr 1999, ABANDONED
PRAI GB 1996-21469 19961015
GB 1996-21885 19961021
DT Utility
FS APPLICATION
LREP HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for **typing** a sample of a **prion** or spongiform encephalopathy disease, a kit suitable for use in such a **typing** method, a method for identifying infection in an animal and/or tissue of bovine spongiform encephalopathy (BSE), a method for assessing and/or predicting the susceptibility of an animal to BSE, a kit for use in such an assessment and/or prediction method, a method for the treatment of a **prion** disease, and compounds suitable for such a method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>